1-Benzyl-6-methylbenzimidazol | 24780-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-Benzyl-6-methylbenzimidazol
• 英文别名: 6-Methyl-1-benzyl-benzimidazol；1-benzyl-6-methyl-1H-benzoimidazole；1-benzyl-6-methyl-1H-benzimidazole；1-benzyl-6-methylbenzimidazole
• CAS: 24780-82-3
• 化学式: C₁₅H₁₄N₂
• 分子量: 222.29
• InChiKey: PUWFVSWRUGFHTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Benzyl-6-methylbenzimidazol 、 C₈H₁₅F₃OSi 在 2,4,5,6-四(9H-咔唑-9-基)异酞腈 作用下， 以70 %的产率得到
  参考文献：
  名称：

  Visible-light-induced organocatalyzed C(sp2)-H bond functionalization of 1,3-azoles with trifluoroacetylsilanes

  摘要：

  DOI：

  10.1007/s11426-024-2203-5

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130281433A1

  公开（公告）日：2013-10-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20160326162A1

  公开（公告）日：2016-11-10

  Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R 1 , R 2 , Q 1 , Q 2 , and Q 3 , are described in this disclosure, compositions thereof, and methods and uses thereof.

  公式I的化合物：或其药用可接受的盐、溶剂化合物、互变异构体、同分异构体或氘代物，其中R1、R2、Q1、Q2和Q3在本公开中有描述，以及其组合物、方法和用途。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20150133427A1

  公开（公告）日：2015-05-14

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐和药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• Nonaqueous electrolyte and nonaqueous secondary battery
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：US10756394B2

  公开（公告）日：2020-08-25

  The purpose of the present invention is to provide a nonaqueous electrolyte that contains acetonitrile having an excellent balance between viscosity and the dielectric constant and a fluorine-containing inorganic lithium salt, wherein the generation of complex cations comprising a transition metal and acetonitrile is suppressed, excellent load characteristics are exhibited, and increases in internal resistance upon repeated charge/discharge cycles are suppressed; a further purpose of the present invention is to provide a nonaqueous secondary battery. The present invention relates to a nonaqueous electrolyte which contains: a nonaqueous solvent comprising acetonitrile; a fluorine-containing inorganic lithium salt; and a specific nitrogenous cyclic compound typified by benzotriazole.

  本发明的目的是提供一种非水电解液，该电解液含有在粘度和介电常数之间具有极佳平衡的乙腈和含氟无机锂盐，其中包含过渡金属和乙腈的复合阳离子的生成受到抑制，显示出极佳的负载特性，并且在重复充放电循环中内阻的增加受到抑制；本发明的另一个目的是提供一种非水二次电池。本发明涉及一种非水电解液，其中包含：由乙腈组成的非水溶剂；含氟无机锂盐；以及以苯并三唑为典型代表的特定含氮环状化合物。
• BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION
  申请人：Gilead Sciences, Inc.

  公开号：EP3070081B1

  公开（公告）日：2018-02-28